Inflammation & Advanced Longevity Panel

NOVI's most comprehensive longevity screen: 100+ biomarkers, inflammatory markers, biological age assessment (LinAge 2.0), and LucenceINSIGHT multi-cancer early detection testing for up to 50 cancer types.

The NOVI Longevity Max represents the clinic's most complete health assessment, combining advanced inflammation profiling, biological age testing, and multi-cancer early detection into a single cohesive programme. Inflammation is the common upstream driver of cardiovascular disease, cancer, metabolic dysfunction, and accelerated cellular ageing — and NOVI's panel addresses it directly. Inflammatory markers tested include high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6), tumour necrosis factor-alpha (TNF-α), and erythrocyte sedimentation rate (ESR), providing both acute and chronic inflammatory signals. These are assessed alongside a complete metabolic and hormonal panel of 100+ biomarkers (as per the Longevity Start programme), handgrip strength testing, and the LinAge 2.0 biological age methylation clock. The centrepiece of the Max programme is the LucenceINSIGHT multi-cancer early detection (MCED) test — a liquid biopsy blood test capable of detecting circulating tumour DNA signals associated with up to 50 cancer types, including pancreatic, ovarian, colorectal, and lung cancers, often before symptoms develop. Early detection significantly increases treatment success rates, and this technology brings hospital-grade oncology screening to a preventive clinic setting. The full panel is supported by pre- and post-screening doctor consultations, a comprehensive written health report, and a personalised longevity plan accessible via the NOVIFY digital health platform. This programme is particularly suited to individuals over 40, those with a family history of cancer, cardiovascular disease, or metabolic conditions, and health-conscious individuals seeking the deepest possible baseline for a structured longevity programme.